Continuous ketorolac

Phase 3Small molecule

Continuous ketorolac is one of 24 small molecule programs targeting Congenital Heart Disease. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Congenital Heart DiseaseRecruiting

Congenital Heart DiseasePhase 3

Recruiting

Competition

Competitive Landscape

26 competitors in Congenital Heart Disease

#DrugCompanyPhaseTrials

Tracleer

Johnson & Johnson

Approved

1 2

Opsumit

Intropin

Remodulin

Theo-Dur

Jardiance

1 7

Pepcid

KKenvue Brands

Approved

1 8

Inspra

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

1 9

Feraheme

AAzurity Pharmaceuticals

Approved

1 10

Decadron

AAspen Global Incorporated

Approved

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

ApprovedRecruiting

Congenital Heart Disease

NCT04040452

Clinical

Trials by Indication[1]

Congenital Heart Disease1 trial

Continuous Infusion Versus Intermittent Ketorolac for Postoperative Pain Control in Pediatric Cardiac Surgery Patients

Recruiting·PPhoenix Children's Hospital·Approved·NCT04040452·166 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Continuous ketorolac. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Continuous ketorolac compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Continuous ketorolac. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Phoenix Children's Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: PPhoenix Children's Hospital

Continuous ketorolac

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Congenital Heart Disease1 trial

References

Drug Info

Quick Facts

Related News